This study aims to better understand how mpox is spreading in the DRC, how it affects different groups of people, and how well vaccines protect against it. The study is designed as a cross-sectional survey, meaning researchers will collect and analyze data from patients diagnosed with mpox at a single point in time. It will also use a case-control approach, comparing people who test positive for the virus to those who test negative, to identify risk factors and evaluate the effectiveness of the vaccine.
Apply to be tested for VMPX at HGR or another test center.
Patients of all ages and sexes. However, minors under the age of 12 are excluded from questions on sex life.
The patient or his/her culturally acceptable representative is willing and able to give informed consent for participation in the study.
NA
Institute of Tropical Medicine, Belgium
Lead sponsor
University of Manitoba
Collaborator
Catholic University of Bukavu, Democratic Republic of Congo
Collaborator
University of Bern
Collaborator
Alliance for International Medical Action
Collaborator
Institut de Recherche pour le Developpement
Collaborator
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
Collaborator
European and Developing Countries Clinical Trials Partnership (EDCTP)
Collaborator
University of California, Los Angeles
Collaborator